Ravuconazole: Eisai/Bristol-Myers Squibb

Current Opinion in Investigational Drugs

Volumn 3, Issue 4, 2002, Pages 555-561

  Arikan, Sevtap ^a   Rex, John H ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; NELFINAVIR; POSACONAZOLE; RAVUCONAZOLE; RIFAMPICIN; SIMVASTATIN; TRIAZOLE DERIVATIVE; VORICONAZOLE; ANTIFUNGAL AGENT; THIAZOLE DERIVATIVE;

ABDOMINAL ABSCESS; ABDOMINAL PAIN; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; CANDIDA KRUSEI; CANDIDIASIS; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MARKETING; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; HEADACHE; HUMAN; LUNG ASPERGILLOSIS; LUNG MYCOSIS; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NONHUMAN; OUTCOMES RESEARCH; PHARMACODYNAMICS; PRURITUS; REVIEW; STRUCTURE ACTIVITY RELATION; THRUSH; ANIMAL; METABOLISM; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMAL; ANTIFUNGAL AGENTS; CLINICAL TRIALS; HUMAN; MYCOSES; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; TRIAZOLES; ANIMALS; HUMANS;

EID: 0035988839     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. ER-30346, a novel antifungal triazole: I. Synthesis and structure-activity relationships of new thiazole-containing triazole antifungals
2. Bristol-Myers Squibb acquires novel antifungal from Eisai
3. Total chiral synthesis of azole antifungals via α-hydroxylation of ketones
4. Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis
5. In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum
6. New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones
7. A novel route for chiral synthesis of the triazole antifungal ER-30346
8. Synthesis and antifungal activity of novel thiazole-containing triazole antifungals. II. Optically active ER-30346 and its derivatives
9. 14C-labeled ER-30346, a novel antifungal triazole
10. In vitro activity of the new triazole BMS-207147 against Aspergillus species, Candida species and emerging mold pathogens: A comparative study
11. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents
12. Therapy of Candida infections: Susceptibility testing, resistance and therapeutic options
13. Drug development pipeline: BMS-207147
14. In vitro activity of a new oral triazole, BMS-207147 (ER-30346)
15. Current and emerging azole antifungal agents
16. In vitro susceptibilities of Candida blood stream isolates to the new triazole antifungal agents BMS-207147, Sch56592 and voriconazole
17. In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America
18. In vitro antifungal activity of BMS-207147 and itraconazole against yeast strains that are non-susceptible to fluconazole
19. In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B
20. Ravuconazole single ascending oral dose study in healthy subjects
21. Ravuconazole: Multiple ascending oral dose study in healthy subjects
22. In vivo characterization of the pharmadynamics of ravuconazole (RAV) in a neutropenic murine disseminated candidiasis model
23. Effect of ravuconazole on the pharmacokinetics of simvastin in healthy subjects
24. In vitro activity of newer antifungals agents against invasive yeast isolates from cancer patients
25. Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis
26. Germinated and nongerminated conidial suspensions for testing of susceptibilities of Aspergillus species to amphotericin B, itraconazole, posaconazole, ravuconazole and voriconazole
27. In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans
28. In vitro and in vivo activities of the triazole derivative BMS-207147 (ravuconazole) against Trypanosoma cruzi, the causative agent of Chagas disease
29. Ravuconazole does not affect the pharmacokinetics of nelfinavir
30. Postantifungal effect of older and newer antifungal agents on Aspergillus fumigatus and Candida albicans
31. Species distribution and antifungal susceptibility (AFS) patterns for Candida bloodstream isolates from the SENTRY participants group [Europe] 1999-2000
32. In vitro susceptibility and azole resistance among clinical and laboratory-selected isolates of Aspergillus flavus obtained from three continents
33. Effect of human serum (HS) or cerebrospinal fluid (CSF) on anticryptococcal activity of new azoles: Differences between Cryptococcus neoformans (CN) var neoformans serotype A and CN var gattii serotypes B and C
34. In vitro activity of investigational triazoles against Trichosporon species
35. Ravuconazole exposure-response relationship in HIV+ patients with oropharyngeal candidiasis
36. Randomized, double-blind study of safety and antifungal activity of ravuconazole relative to fluconazole in esophageal candidiasis
37. Efficacy of ravuconazole in treatment of invasive pulmonary aspergillosis in persistently neutropenic rabbits
38. In vitro activities of four novel triazoles against Scedosporium species
39. International surveillance of bloodstream infections due to Candida species: Frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program
40. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model
41. Correlation of the ravuconazole (RAV) AUC/MIC ratio associated with efficacy against 8 Candida albicans strains in a neutropenic murine model
42. Effect of ravuconazole, a new triazole antifungal, in a rat intraabdominal abscess model
43. Efficacy of ravuconazole in treatment of mucosal candidosis in SCID mice
44. Bristol-Myers Squibb
45. Efficacy of ravuconazole for the treatment of systemic murine histoplasmosis
46. Efficacy of ravuconazole for the treatment of systemic murine histoplasmosis